A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study
Authors:
- 1 January 2017
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 112 (1) , 172-183
Abstract
Ets. METHODS: The expression of MUC5AC in benign pancreatic pathologies, PC precursor lesions, primary PC tissues and metastatic lesions was evaluated by immunohistochemistry. Circulating MUC5AC levels were measured using sandwich ELISA assay developed in-house, and CA19-9 was measured using radioimmunoassay. A combined training set (n=346) was used to evaluate the diagnostic (n=241) and predictive (n=105, total samples 201 from pre- and post-surgical and chemotherapy set) significance of MUC5AC. Results were further validated with a pre-defined cut-off value using independent sets from the Mayo Clinic (n=94) and the University of Pittsburgh Medical Center (n=321). RESULTS: Tissue expression analyses indicated thede novoexpression of MUC5AC in pancreatic intraepithelial precursor lesions 1A (PanIN1A); the expression was maintained through all stages of progression to invasive adenocarcinoma. The median circulating MUC5AC levels in patients with resectable early-stage PC (EPC) (stage 1/2; 67.2 ng/ml, IQR: 23.9–382.1) and unresectable late-stage PC (LPC) (stage 3/4; 389.7 ng/ml, IQR: 87.7–948.6) were significantly higher compared with (P-value ≤0.0001) benign controls (BC) (7.2 ng/ml, IQR: 0.4–26.5) and (P-value ≤0.0001) chronic pancreatitis (CP) controls (8.4 ng/ml, IQR: 1.5–19.2). In the diagnostic training set (n=241), MUC5AC efficiently differentiated EPC from healthy controls (HC) (83%/80% sensitive (SN)/specific (SP)), BC (67%/87% SN/SP), and CP (83%/77% SN/SP). Independent validation sets from the Mayo Clinic and UPMC confirmed the diagnostic potential of MUC5AC to differentiate EPC from BC (68%/73%; 65%/83%) and CP (68%/79%; 65%/72%). Furthermore, MUC5AC and CA19-9 combination significantly improved (p-value < 0.001) the diagnostic accuracy for differentiating resectable cases from controls. CONCLUSIONS: MUC5AC is a valuable diagnostic biomarker, either alone or in combination with CA19-9, to differentiate PC from CP and benign controls....Keywords
This publication has 23 references indexed in Scilit:
- Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucinMolecular Cancer, 2013
- Early Diagnosis of Pancreatic Cancer: Challenges and New DevelopmentsBiomarkers in Medicine, 2012
- PAM4 enzyme immunoassay alone and in combination with CA 19‐9 for the detection of pancreatic adenocarcinomaCancer, 2012
- Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaborationBMC Medicine, 2012
- Serum Biomarker Panels for the Detection of Pancreatic CancerClinical Cancer Research, 2011
- Serum biomarkers for improved diagnostic of pancreatic cancer: a current overviewJournal of Cancer Research and Clinical Oncology, 2010
- Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status reportAnnals of Oncology, 2009
- Diagnostic and Prognostic Value of Plasma Tumor M2 Pyruvate Kinase in Periampullary CancerPancreas, 2007
- New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From PancreatitisJournal of Clinical Oncology, 2006
- Molecular Markers of Early Pancreatic CancerJournal of Clinical Oncology, 2005